CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families - PubMed (original) (raw)

CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families

N A Gruis et al. Melanoma Res. 1995 Jun.

Abstract

Combined multi-point linkage analysis in seven Dutch families with FAMMM syndrome confirmed the location of a melanoma susceptibility (MLM) gene in the 9p21 area. The occurrence of a shared high-risk haplotype in six of the families strongly suggests a founder effect in the Leiden region. No indication for locus heterogeneity was observed. Recently, the CDKN2 (p16) gene, an important regulator of the cell cycle, was isolated from the 9p21 region. A 19-bp germline deletion in the CDKN2 gene was detected in the high-risk haplotype, suggesting CDKN2 to be identical to MLM. Loss of heterozygosity studies in melanoma and pancreatic carcinoma from gene carriers strongly support the view that CDKN2 is a general tumour suppressor gene predisposing not only to melanoma but also to other malignancies. Interestingly, the occurrence of apparent clinical FAMMM cases with melanoma but without the high-risk deletion haplotype suggests the necessity of additional (naevus) genes to explain the complete FAMMM phenotype.

PubMed Disclaimer

Cited by

Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines.
Chau C, van Doorn R, van Poppelen NM, van der Stoep N, Mensenkamp AR, Sijmons RH, van Paassen BW, van den Ouweland AMW, Naus NC, van der Hout AH, Potjer TP, Bleeker FE, Wevers MR, van Hest LP, Jongmans MCJ, Marinkovic M, Bleeker JC, Jager MJ, Luyten GPM, Nielsen M. Chau C, et al. Cancers (Basel). 2019 Aug 4;11(8):1114. doi: 10.3390/cancers11081114. Cancers (Basel). 2019. PMID: 31382694 Free PMC article.
Familial melanoma: a complex disorder leading to controversy on DNA testing.
de Snoo FA, Bergman W, Gruis NA. de Snoo FA, et al. Fam Cancer. 2003;2(2):109-16. doi: 10.1023/a:1025758527675. Fam Cancer. 2003. PMID: 14574160 Review.
CDKN2A germline mutations in familial pancreatic cancer.
Bartsch DK, Sina-Frey M, Lang S, Wild A, Gerdes B, Barth P, Kress R, Grützmann R, Colombo-Benkmann M, Ziegler A, Hahn SA, Rothmund M, Rieder H. Bartsch DK, et al. Ann Surg. 2002 Dec;236(6):730-7. doi: 10.1097/00000658-200212000-00005. Ann Surg. 2002. PMID: 12454511 Free PMC article.
Founder effect at PGL1 in hereditary head and neck paraganglioma families from the Netherlands.
van Schothorst EM, Jansen JC, Grooters E, Prins DE, Wiersinga JJ, van der Mey AG, van Ommen GJ, Devilee P, Cornelisse CJ. van Schothorst EM, et al. Am J Hum Genet. 1998 Aug;63(2):468-73. doi: 10.1086/301951. Am J Hum Genet. 1998. PMID: 9683583 Free PMC article.
Molecular signatures of pancreatic cancer.
Hong SM, Park JY, Hruban RH, Goggins M. Hong SM, et al. Arch Pathol Lab Med. 2011 Jun;135(6):716-27. doi: 10.5858/2010-0566-RA.1. Arch Pathol Lab Med. 2011. PMID: 21631264 Free PMC article. Review.

CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families - PubMed (original) (raw)